The ear contains the only place on the body’s surface where a branch of the vagus nerve is accessible through the skin. The auricular branch of the vagus nerve (ABVN), also called Arnold’s nerve, innervates specific regions of the outer ear — primarily the cymba conchae, the tragus, and parts of the ear canal. This anatomical quirk has made the ear the primary target for non-invasive vagus nerve stimulation, and several devices now exploit it for conditions ranging from tinnitus to depression.
How Auricular VNS Works
Transcutaneous auricular vagus nerve stimulation (taVNS) delivers low-level electrical current through electrodes placed on the ear at points where the ABVN is most superficial. The electrical signal travels along the auricular branch to the brainstem, reaching the nucleus tractus solitarius (NTS) — the same relay station where implanted vagus nerve stimulators send their signals.
Functional MRI studies have confirmed this pathway. When electrical stimulation is applied to the cymba conchae (the inner ridge of the ear), brain activation patterns closely resemble those seen with invasive cervical VNS — including activation of the NTS, locus coeruleus, and limbic regions, with deactivation of the default mode network. Stimulation of the earlobe, which lacks ABVN innervation, does not produce these patterns, making it a useful sham control in research.
The stimulation parameters vary across devices and studies, but typical settings use a pulse width of 200-300 microseconds, a frequency of 20-30 Hz, and current intensity adjusted to the individual’s perception threshold — usually strong enough to feel tingling but below the pain threshold, typically 0.5-5 milliamps.
Lenire: Bimodal Neuromodulation for Tinnitus
Lenire, developed by Neuromod Devices (Dublin, Ireland), is the first device to receive FDA De Novo authorisation specifically for tinnitus treatment. It uses a different approach from standard taVNS: bimodal neuromodulation, pairing mild electrical stimulation of the tongue with precisely timed sound delivered through headphones.
The tongue component (the Tonguetip) is an intra-oral device with 32 electrodes that delivers gentle electrical pulses to the lingual nerve. This stimulus is synchronised with auditory tones delivered to both ears through Bluetooth headphones. The theory is that pairing two sensory inputs drives neuroplastic changes in the auditory cortex, reversing the maladaptive neural reorganisation thought to underlie chronic tinnitus — a concept called targeted plasticity therapy.
The TENT-A3 trial, published in Nature Communications in 2024, enrolled 112 participants across three sites. After a six-week sound-only control period, participants received six weeks of bimodal Lenire treatment. Among those with moderate or worse tinnitus who showed no meaningful improvement from sound alone, 70.5% reported clinically significant improvement after Lenire treatment, measured by the Tinnitus Handicap Inventory. Treatment adherence was 82.4%, 88.6% of participants said they would recommend the device, and no device-related serious adverse events were reported. Earlier large-scale trials suggest benefits can persist for at least 12 months.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Clinician-applied tVNS
- Implanted VNS and neuromodulation
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
gammaCore: Cervical VNS
The gammaCore device (electroCore) takes a different anatomical approach — it stimulates the cervical vagus nerve at the neck rather than the ear. Two flat electrodes are placed on the skin overlying the vagus nerve in the carotid triangle, and the device delivers a proprietary electrical waveform. gammaCore is FDA-cleared for the acute treatment and prevention of migraine and cluster headache, and for the acute treatment of episodic cluster headache.
While gammaCore is not an ear-based device, it is the most widely available non-invasive VNS device and the one most commonly compared with auricular approaches in research. Its clinical evidence base is substantially larger than that of auricular devices for most conditions, with multiple randomised controlled trials supporting its use in headache disorders.
NEMOS, Parasym, and Research Devices
The NEMOS system (tVNS Technologies, Germany) was one of the first dedicated auricular VNS devices. It delivers stimulation to the cymba conchae via a custom ear electrode connected to a stimulator unit. NEMOS received a CE mark in Europe for epilepsy and depression, and has been used extensively in academic research — many of the fMRI studies confirming that auricular stimulation activates central vagal pathways used NEMOS or its research equivalent.
The Parasym Nuropod (Parasym, UK) is a more recent auricular device designed for home use. It targets the tragus and has been used in clinical studies investigating taVNS for atrial fibrillation, heart failure, and inflammatory conditions. A notable trial (TREAT AF, published in JACC: Clinical Electrophysiology) found that daily tragal stimulation over 6 months reduced atrial fibrillation burden in patients with paroxysmal AF, pointing to potential cardiac applications beyond the conditions traditionally associated with VNS.
Several consumer-grade “vagus nerve stimulation” earpieces have also entered the market, typically marketed for stress reduction and relaxation. These devices generally lack the rigorous clinical validation of prescription devices, and their stimulation parameters may not match those shown to activate central vagal pathways in research. The distinction between a research-validated medical device and a consumer wellness product is important for anyone considering auricular VNS.
Clinical Evidence Beyond Tinnitus
Auricular VNS is under active investigation for a broad range of conditions. The most advanced evidence beyond tinnitus includes:
Depression: Multiple randomised trials have tested taVNS for major depressive disorder. A 2022 meta-analysis found statistically significant but modest improvements in depressive symptoms compared to sham, with effect sizes smaller than those seen with implanted VNS. Larger, longer trials are needed to establish clinical utility.
Epilepsy: NEMOS has a CE mark for drug-resistant epilepsy based on pilot data showing seizure frequency reduction, though the evidence base is smaller than for implanted VNS, which remains the standard neurostimulation approach for epilepsy.
Inflammation: Building on Kevin Tracey’s cholinergic anti-inflammatory pathway research, several groups are testing whether taVNS can suppress inflammatory cytokines in conditions like rheumatoid arthritis and inflammatory bowel disease. Early-phase results are encouraging but preliminary.
Cardiac: Beyond the TREAT AF trial, ongoing studies are investigating taVNS for heart failure and post-myocardial infarction recovery.
Safety and Practical Considerations
A 2022 systematic review of taVNS safety found that serious adverse events are extremely rare. The most commonly reported side effects are mild and local: tingling or pain at the electrode site, skin irritation, headache, and occasional dizziness. These typically resolve with parameter adjustment or electrode repositioning.
Contraindications include implanted cardiac devices (pacemakers, defibrillators) due to theoretical electromagnetic interference risk, and active ear infections or skin lesions at the electrode site. Pregnancy is generally listed as a contraindication due to lack of safety data, not demonstrated harm.
For anyone considering auricular VNS, the key practical distinction is between FDA-cleared/CE-marked medical devices (Lenire, NEMOS, gammaCore) and consumer wellness products. Medical devices have undergone clinical testing, use validated stimulation parameters, and are typically prescribed and fitted by a healthcare professional. Consumer devices may or may not use effective parameters, and their marketing claims often exceed their evidence base.
Want to understand the full science behind vagus nerve stimulation — what works, what doesn’t, and why? Get My Vagus Nerve & Me eBook for a comprehensive, evidence-based guide.
